AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning

The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech s shares collapsed.